

Exploitable knowledge (description)	Potentially exploitable products	Sector of application	Timetable for commercial use	Patents or other IPR protection envisaged	Owners and other interested parties
1. Novel biomarkers of telomere function of potential clinical value. Mean telomere length (in blood samples), human genetic polymorphisms associated with TL variations, TRF1, Rap1, SIRT1, MSH2, ATM, TRF2, Apollo.	Cancer biomarkers for diagnostic and prognostic evaluations. Anticancer drug leads.	Medical/clinical Cancer treatment Cancer diagnosis	Month 36 onwards	IP protection of genuinely novel and clinically validated biomarkers/anti-cancer targets/new test protocols envisaged	All TeloMarker Partners.
2. Novel biomarkers of telomere dysfunction (derived from in vitro & in vivo model systems) of potential clinical value. S100A6, SFN, EZR, PRDX1, PRDX2, PARK7, S100A4, KLK5, SERPINB5, Kai1 (metastasis), TNKS2 & Pot1 (breast cancer), CRAMP, Chi3L3, NAG, EF-1alpha, Stathmin, p53 checkpoint components (eg p21).	Cancer biomarkers for diagnostic and prognostic evaluations. Anti-cancer targets Anticancer drug leads.	Medical/clinical Cancer treatment Cancer diagnosis	Month 36 onwards	IP protection of genuinely novel and clinically validated biomarkers/anti-cancer targets/new test protocols envisaged.	All TeloMarker Partners.
3. Novel anti-cancer drug targets based on known or newly discovered (in TeloMarker) telomerase or associated telomere maintenance mechanisms.	Anti-cancer targets Anti-cancer drug leads	Medical/clinical Cancer treatment	Month 36 onwards	Patent protection of drug leads that pass preclinical evaluation possible	All TeloMarker Partners.

TeloMarker: Summary overview of potentially exploitable foreground

4. Novel genes and proteins involved in telomerase regulation and telomere maintenance discovered during TeloMarker. Telomerase hTERT negative regulator SETD2 (breast cancer) chromosome-11-linked novel telomerase repressor (prostate cancer), acacetin, chrysin chromatin remodeling factors), blood plasma hTERT levels in prostate cancer	Anti-cancer targets, cancer diagnostics protocols. DNA sequences for use in gene therapy RTD.	Medical/clinical Cancer research Cancer treatment Cancer diagnosis	Month 36 onwards	IP protection of genuinely novel targets, telomerase repressor genes, possible	All TeloMarker Partners.
5. Novel, improved assays for quantifying telomerase and telomere lengths that can be used in a clinical setting, and/or for anti-telomerase drug screening. 'TeloSpot' telomerase assay; 96-well Ad-hTRmut assay. Sulphoquinovosyl diacylglycerols identified by	Cancer diagnostic kits Drug screens	Medical/clinical Cancer diagnostics applications Anti-cancer drug screening	Month 36 onwards	Patent protection of assays/screens and novel telomerase inhibitors possible.	All TeloMarker Partners.

TeloSpot as potent telomerase inhibitors.					
---	--	--	--	--	--